Biovail to pay up to $65 million for U.S., Canadian rights to Parkinson’s drug

Published June 4, 2010

Biovail to pay up to $65 million for U.S., Canadian rights to Parkinson’s drug
TORONTO – Biovail Corp. (TSX:BVF) has agreed to pay up to US$65 million plus royalties for the U.S. and Canadian rights to a development stage